Core Viewpoint - Rosen Law Firm is reminding investors who purchased or sold Cepton, Inc. (NASDAQ: CPTN) common stock between July 29, 2024, and January 6, 2025, of the December 8, 2025, lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 8, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly [6]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements regarding Cepton's business and operations [5]. - Specific allegations include that Cepton received a credible third-party bid valuing the company at more than double the Koito Acquisition, which was not disclosed to shareholders [5]. - The Board of Directors allegedly failed to explore this offer meaningfully, depriving shareholders of the opportunity to consider the Koito Acquisition [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of aTyr Pharma, Inc. to secure legal counsel before the December 8, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - The class period for the aTyr Pharma securities class action is from January 16, 2025, to September 12, 2025 [2]. - Investors who purchased common stock during this period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by December 8, 2025 [4]. Group 2: Legal Representation - Investors are advised to choose qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [5]. - The Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [5]. Group 3: Case Allegations - The complaint alleges that aTyr Pharma provided misleading statements regarding the efficacy of its drug Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage completely [6]. - The lawsuit claims that when the true information became public, investors suffered damages as a result [6].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Freeport-McMoRan Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Freeport securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees, facilitated by a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Freeport [2]. Group 2: Incident Impact - On September 24, 2025, Freeport released an update regarding a mud rush incident at the Grasberg Block Cave mine in Indonesia, which resulted in the fatal injuries of two team members [3]. - Following the announcement of this incident, Freeport's stock experienced a significant decline of 16.95% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering substantial amounts for its clients [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers and acquirers of Synopsys, Inc. securities for the period between December 4, 2024, and September 9, 2025, due to alleged misleading statements and failure to disclose material adverse facts about the company's business and operations [1][5]. Group 1: Lawsuit Details - The lawsuit claims that during the Class Period, Synopsys made materially false and misleading statements regarding its business focus on artificial intelligence customers, which negatively impacted its Design IP business economics [5]. - Defendants allegedly failed to disclose that certain decisions regarding road maps and resources were unlikely to yield intended results, leading to a material negative impact on financial results [5]. - The lawsuit asserts that the positive statements made by the defendants about Synopsys' business lacked a reasonable basis and were materially misleading [5]. Group 2: Participation Information - Investors who purchased Synopsys securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must move the Court by December 30, 2025, to represent other class members in directing the litigation [1][3].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by claims that Agilon Health may have provided misleading information to investors [1]. - Shareholders who purchased Agilon Health securities may be entitled to compensation through a class action without any out-of-pocket fees [2]. Group 2: Company Performance - On August 4, 2025, Agilon Health reported its second-quarter results, indicating that industry headwinds were more severe than previously anticipated [3]. - Following the announcement, Agilon Health's stock experienced a significant decline of 51.5% on August 5, 2025 [3]. Group 3: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4]. - The firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Tandem Diabetes Care securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. Group 2: Company Incident and Stock Impact - On August 7, 2025, Tandem Diabetes Care announced a voluntary medical device correction for select t:slim X2 insulin pumps due to a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial prospects during the specified Class Period from December 4, 2024, to September 9, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Synopsys failed to disclose significant adverse facts about its business, particularly regarding its focus on artificial intelligence customers, which negatively impacted its Design IP business [5]. - Defendants allegedly made positive statements about Synopsys' business that were misleading and lacked a reasonable basis, leading to investor damages when the truth was revealed [5]. Group 2: Investor Information - Investors who purchased Synopsys securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in previous years, including over $438 million secured in 2019 [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Inspire Medical Systems, Inc. common stock during the specified Class Period, indicating potential misrepresentation by the company regarding its product, Inspire V [1][5]. Group 1: Lawsuit Details - The class action lawsuit is filed for investors who purchased Inspire Medical common stock between August 6, 2024, and August 4, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that Inspire Medical misrepresented the market demand for its sleep apnea device, Inspire V, and failed to disclose necessary steps for its launch, leading to investor damages when the truth was revealed [5]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the court by January 5, 2026, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in previous years [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Zions Bancorporation due to allegations of materially misleading business information issued by the company [1] Group 1: Legal Actions and Investigations - Rosen Law Firm is preparing a class action to seek recovery of investor losses for those who purchased Zions Bancorporation securities [2] - Zions Bancorporation announced a $50 million charge-off for a loan due to misrepresentations and contractual defaults by borrowers, and will engage counsel for an independent review [3] Group 2: Market Reaction - Following the announcement of the charge-off, Zions Bancorporation's common stock experienced a decline of 13.14% on October 16, 2025 [4] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field, including being ranked No. 1 for securities class action settlements in 2017 [5]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Freeport-McMoRan Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Compensation - Shareholders who purchased Freeport securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. - A class action is being prepared by Rosen Law Firm to seek recovery of investor losses [2]. Group 2: Incident Impact - On September 24, 2025, Freeport issued a press release regarding a mud rush incident at the Grasberg Block Cave mine in Indonesia, which resulted in the fatal injuries of two team members [3]. - Following this announcement, Freeport's stock experienced a significant decline of 16.95% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering substantial amounts for its clients [4].